anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In one aspect, a computerized method for generating a personalized digital software application comprising: providing an application modeler engine. With the application modeler engine the method provides a graphical display of a palate that comprises a list all the nodes that are available to include in an application definition file(s). The application modeler engine receives a set of nodes via a drag and drop operation into the application definition file. The application modeler engine defines and integrates a chatbot into the personalized digital software application. The application modeler engine automatically creates the application definition file to run on a mobile device of the patient, wherein the application definition file follows a protocol and logic created in the application by a care team and the drag and dropped nodes. The application modeler engine uses the application definition file to generate the application from the application definition file. The application modeler engine deploys the application to a user's mobile device.
BACKGROUND: Vitamin C deficiency, or scurvy, is rare but poses risks for children with poor diets, limited resources, or malabsorption issues. It may also be common in children with restrictive or selective dietary habits in children with global developmental delay, autism spectrum disorder, and physical disabilities. Symptoms include fatigue, irritability, joint and muscle pain, joint swellings, edema, swollen gums, easy bruising, and delayed wound healing. Early recognition and prompt intervention are essential to prevent the progression of symptomatic vitamin C deficiency in children.
CASE PRESENTATION: We present a case of a 13-year-old boy with developmental delay secondary to Lennox Gastaut syndrome referred for suspected recurrent, severe, and atypical IgA vasculitis. He presented with irritability, loss of appetite, petechial and ecchymotic lower limb lesions, unilateral gum swelling, severe arthritis, peripheral oedema, severe weight loss, anaemia, and raised inflammatory markers. Multiple investigations were performed before the diagnosis of scurvy was made. A surgical finding of friable gingival tissue with multiple loose teeth, a skin biopsy with follicular hyperkeratosis and extravasated perifollicular red blood cells, and a typical X-ray finding led to the diagnosis of scurvy.
CONCLUSION: Scurvy should be given careful consideration as a differential diagnosis in patients presenting with musculoskeletal issues, mucocutaneous complaints, and constitutional symptoms such as malaise, asthenia, irritability, and loss of appetite. A focused and detailed dietary history looking for a lack of good sources of vitamin C can be an easy indicator of this differential. Imaging studies revealing the typical features can also help make the diagnosis. Pathology of the skin revealing pathognomonic features can add to the certainty of the diagnosis. In the absence of all else, the rapid response to treatment with an appropriate dose of vitamin C has a diagnostic and therapeutic role.
The transaction management system 100 includes a plurality of individually identifiable secure container holding facilities constituted by cash acceptance terminals 112 located at the premises of participating merchants 114 and a plurality of individually identifiable secure containers or cash containers, each adapted to dock with and un-dock from a cash acceptance terminal 112. The merchants 114, in each transaction, deposit transaction documents such as money, cheques, credit card vouchers or the like into the secure container within the cash acceptance terminal 112. Cash money fed into the cash acceptance terminal is scanned, validated and counted into the secure container. The cash acceptance terminals 114 include data entry facilities by means of which data pertaining to transactions is recorded in the cash acceptance terminal. The secure containers and the cash acceptance terminals 112 are adapted for bidirectional communication and the data recorded in the cash acceptance terminal 112 is communicated to the secure container. The transaction management system 100 includes a central server 118 in communication with the data processing system of a number of financial institutions 120, The cash acceptance terminals 112 are programmed to communicate with the server 118. Purchasers 116 are able to use the cash acceptance terminals 112 as banking facilities and, using a cash acceptance terminal with a facility to recirculate and to dispense cash, the system may be programmed to allow the cash acceptance terminals 112 to dispense cash and credit value, thereby allowing a purchaser to use a cash acceptance terminal 112 like an automated teller machine (ATM) to draw cash, to transfer money between accounts, for bill payment or the like. Using an appropriate tracking and scheduling system, the central server 118 is programmed to record the identity and location of each cash acceptance terminal and every secure container in the system 100 as well as the monetary value stored in or to be obtained from each cash acceptance terminal and secure container in the system which enables the system operator and participating financial institutions 120 to manage the flow of cash within the system 100 without necessarily routing each cash consignment through a cash processing centre 124 or financial institution 120. The transaction management system 100 is essentially a cash bank with a cash repository that is not constituted by a conventional vault, but by a virtual repository constituted by the secure cash acceptance terminals 112 and secure containers that are all tracked and audited by the system 100.
Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS: General).

Carcinogenesis, Mutagenesis, Impairment of Fertility: Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.

Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of Salmonella typhimurium strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcg/mL, and in the Aspergillus nidulans non-disjunction assay at an unspecified concentration.

Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.
Group I will be given a complex of balneological procedures: swimming pool 20 min, 34-36° mineral/geothermal water procedure 20 min, sapropel wrapping 20 min, salt therapy 25 min. Duration of treatment - 6 days, outpatient.
FIELD: medicine, pharmacology. SUBSTANCE: invention relates to powder-like compositions comprising stabilized unilamellar liposomes. The composition contains at least one external lipid phase and internal aqueous polar core gelatinized at room temperature. Invention relates to method for preparing these compositions and their using as food supplements and in pharmaceutical compositions designated for oral route of administration (effect on lipemia). Named compositions consist of mainly unilamellar liposomes comprising external lipid phase consisting of mainly lipids of class 4 (phospholipids) and internal aqueous core consisting of mainly mixture M of at least two different non-polymerizing gel-forming agents G1 and G2 characterizing by phase transition point in system gel-sol above or equal to 37 C under condition that G1 represents gel-forming agent taken among gelatin and carragheenan and G2 is taken among carragheenan. Liposomes have diameter from 20 nm to 1 μm being mainly from 50 to 500 nm and they are represented as particles with mean diameter from 10 to 1 000 μm formed by one or some indicated above liposomes. Liposomes are covered by envelope taken among group including dehydrated thermoreversible aqueous gel that is identical with aqueous gel of internal core, dextrins or mixture of dextrins. Invention provides preparing the stable powder composition based on liposomes. EFFECT: valuable properties of compositions. 21 cl, 9 tbl, 7 dwg, 6 ex
Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
BACKGROUND: Migraine is a primary headache defined as moderate-to-severe pain lasting 4 to 72 h, ranking 2nd among the disabling conditions for both genders regardless of the age and the greater occipital nerve (GON) block has been reported as an efficient treatment method for migraine. The present study aims to evaluate and compare the efficiency of the two methods of GON block, i.e., the ultrasound (US)-guided technique and the landmark-based technique.
METHOD: Having a prospective and randomized design, the study assigned the patients with chronic migraine into two groups after which a neurologist performed landmark-based GON block in the first group while an algologist performed US-guided GON block in the second group. During the 3-month follow-up period, the number of days with pain, the duration of pain, the number of analgesic drugs taken in a month, and Visual Analogue Scale (VAS) scores were compared with the values ​​before treatment and at the 1st week, 1st month, and 3rd month after treatment.
RESULTS: US-guided GON block group included 34 patients while there were 32 patients in the landmark-based GON block group. US-guided GON block group showed significantly reduced VAS scores and frequency of attacks compared to the landmark-based GON block group at Month 1 after the procedure. After a 3-month follow-up period of the two groups, the frequency of attacks, analgesic intake and the duration of attacks were lower in both groups compared to the baseline. At 3-month follow-up, the mean of VAS scores decreased from 9,47 ± 2,69 to 4,67 ± 1,9 in US-guided GON block group and from 9,46 ± 0,98 to 7 ± 2,5 in the landmark-based GON block group.
CONCLUSION: It was determined that both US-guided and landmark-based GON block were efficient techniques in patients with chronic migraine. US-guided GON block technique resulted in lower VAS scores, shorter durations of pain, lower frequencies of attack, and lower intake of analgesics compared to the landmark-based GON block technique.
Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
Eosinophil-mediated pathophysiology is tissue destructive and tissue altering with proinflammatory, prothrombotic, and profibrotic effects. The distinctive morphology of an eosinophil reveals a cytoplasm chockfull of unique granules, and the granule proteins have numerous toxic effects on cells, tissues, and organs. Eosinophils are not found in most human tissues, and eosinophil involvement in diseased tissues generally is identified by cell infiltration on histopathologic examination. However, eosinophils characteristically lose their structural integrity and deposit granules and granule proteins at sites of inflammation. Hence, their participation in tissue damage may be underrecognized or entirely overlooked. The eosinophil major basic protein 1 is a toxic granule protein and, when deposited, persists in tissues. Major basic protein 1 deposition can be regarded as a footprint of eosinophil activity. Analyses of numerous eosinophil-related diseases have demonstrated clear-cut evidence of major basic protein 1 deposition in affected tissues where eosinophils were not recognized by hematoxylin and eosin tissue staining and light microscopy. Eosinophil granule protein deposition, as exemplified by localization of major basic protein 1, especially when disproportionately greater than cellular infiltration, emerges as a biomarker of hidden eosinophil-related pathophysiology. Consequently, current assessments of recognized eosinophils may vastly underestimate their role in disease.
The present invention relates to provide a non-human animal model unresponsive to a synthetic compound wherein a gene function encoding TLR7 that recognizes an immunopotentiating synthetic compound such as imidazoquinoline lacks on is genomic locus. Whole or part of a gene fragment of a gene site including an intracellular region and a transmembrane region of a TLR7 gene obtained from a mouse gene library is replaced by a plasmid including poly A signal and a marker gene to construct a targeting vector. Then, this targeting vector is linearized and transferred into embryonic stem cells. The target embryonic stem cells wherein the TLR7 gene function is deleted are microinjected into a mouse blastocyst to generate a chimeric mouse. Then, this chimeric mouse is crossed with a wild-type mouse to generate a heterozygote mouse. Next, the heterozygote mice are intercrossed to obtain a TLR7 knockout mouse.
Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter \>2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.
Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
The PREDIABETEXT project will involve five WorkPackages (WP). In WP1-4 we will develop and pilot-test the different components of the intervention (WP1 will develop the brief text messages targeted to patients; WP2 will adapt our existing technology system to deliver the messages; WP3 will develop an educational intervention targeted to Primary Healthcare workers, and; WP4 will pilot-test and optimise both interventions). In WP5 we will conduct a phase II, six-month, three-arm, cluster randomised, clinical trial with 42 primary care workers and 420 patients at risk of T2DM (HbA1c from 6% to 6.4% or fasting plasma glucose 110-125mg/dl, or both) registered in Primary Care centres from Mallorca. Patients will be allocated to a control (usual care) group, intervention A (patient messaging intervention), or intervention B (patient messaging intervention plus online education to their primary healthcare workers). The primary outcome will be HbA1c. Secondary outcomes will include additional clinical outcomes, and physiological, behavioural and psychological outcomes.
Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
The incidence of adverse reactions was determined through 36 months in a randomized, multicenter, controlled trial (Study 3) in which 215 renal transplant patients received sirolimus as a maintenance regimen following cyclosporine withdrawal, and 215 patients received sirolimus with cyclosporine therapy [see Clinical Studies (14.2)]. All patients were treated with corticosteroids. The safety profile prior to randomization (start of cyclosporine withdrawal) was similar to that of the 2 mg sirolimus groups in Studies 1 and 2.

Following randomization (at 3 months), patients who had cyclosporine eliminated from their therapy experienced higher incidences of the following adverse reactions: abnormal liver function tests (including increased AST/SGOT and increased ALT/SGPT), hypokalemia, thrombocytopenia, and abnormal healing. Conversely, the incidence of the following adverse events was higher in patients who remained on cyclosporine than those who had cyclosporine withdrawn from therapy: hypertension, cyclosporine toxicity, increased creatinine, abnormal kidney function, toxic nephropathy, edema, hyperkalemia, hyperuricemia, and gum hyperplasia. Mean systolic and diastolic blood pressure improved significantly following cyclosporine withdrawal.

Malignancies

The incidence of malignancies in Study 3 [see Clinical Studies (14.2)] is presented in Table 3.

In Study 3, the incidence of lymphoma/lymphoproliferative disease was similar in all treatment groups. The overall incidence of malignancy was higher in patients receiving sirolimus plus cyclosporine compared with patients who had cyclosporine withdrawn. Conclusions regarding these differences in the incidence of malignancy could not be made because Study 3 was not designed to consider malignancy risk factors or systematically screen subjects for malignancy. 

In addition, more patients in the sirolimus with cyclosporine group had a pre-transplantation history of skin carcinoma.
PROBLEM TO BE SOLVED: To test the sensitivity to an antifungal agent simply and with high reproducibility by a method wherein the antifungal agent is changed into a solid phase on a microplate by a reduced-pressure drying method. SOLUTION: An agent solution which is to be changed into a solid phase on a microplate is prepared in such a way that the agent is dissolved in pure water (UHP), for agent preparetion, which is sterlized in high-pressure steam or that the agent is diluted properly by using the pure water. In the case, in which, for example, amphotericin B, 5-fluorocytosine, fluoconasol or the like is used the an agent, the solution is prepared so that the agent becomes a final concentration. By using the prepared agent solution, a twice-dilution series in a proper concentration range is prepared with sterilized distilled water, the solution is dispensed to a plate in an amount of 40-220μl/well (e.g. 10μl/well). and it is dried under a reduced pressure for 8 to 24 hours (preferably 24 hours) so as to be changed into a soild phase. The prepared plate can be preserved at 4 deg.C.
FIELD: veterinary medicine, veterinary obstetrics. SUBSTANCE: the method deals with a cow's placenta-derived biostimulant used as a tissue preparation for subcutaneous injection. Preparation is first injected for cows at 20 ml dose 10-15 d before calving, and repeatedly for 12 h after calving. Moreover, it is conducted at the background of "Tetravit" prophylaxis which is injected per 10 ml twice a month for the whole dry period. EFFECT: decreased terms of placenta removal and cases of placenta delay, easier removal of delayed placenta. 1 cl, 3 tbl
The steps governing healing with or without fibrosis within the same microenvironment are unclear. After acute kidney injury (AKI), injured proximal tubular epithelial cells activate SOX9 for self-restoration. Using a multimodal approach for a head-to-head comparison of injury-induced SOX9 lineages, we identified a dynamic SOX9 switch in repairing epithelia. Lineages that regenerated epithelia silenced SOX9 and healed without fibrosis (SOX9on-off). By contrast, lineages with unrestored apicobasal polarity maintained SOX9 activity in sustained efforts to regenerate, which were identified as a SOX9on-on Cadherin6pos cell state. These reprogrammed cells generated substantial single-cell WNT activity to provoke a fibroproliferative response in adjacent fibroblasts, driving AKI to chronic kidney disease. Transplanted human kidneys displayed similar SOX9/CDH6/WNT2B responses. Thus, we have uncovered a sensor of epithelial repair status, the activity of which determines regeneration with or without fibrosis.
The invention relates to creped prebiotic tissue products. The tissue products comprise prebiotics in sufficiently high amounts to have a prebiotic effect in use, without negatively affecting tissue product properties, such as tensile strength, stiffness or softness. Thus, in certain embodiments the present invention provides soft, durable creped prebiotic tissue products that are able to improve the growth of healthy bacteria such as Bifidobacterium spp. or Lactobacillus spp. without promoting growth of enteropathogenic bacteria. The tissue products provide these benefits yet have a GMT greater than about 500, a Stiffness Index less than about 20 and a TS7 value less than about 10.
NEW MATERIAL:The heterocyclic compound of formula I [R1 is heterocyclic group selected from 1,2,4-triazoyl, 1,3,5-triazinyl and imidazo-[4,5-C]pyridinyl; X is S or group of formula II; R<2> is pyridinyl or quinolinyl; n is 1 or 2] and its salt. EXAMPLE:2-[(4-Methyl-5-trifluoromethyl-4H-1,2,4-triazol-3-ylth-io)-meth yl]pyridine. USE:It has gastric acid secretion suppressing and antiulcer activities and is useful as an antiulcer agent. PREPARATION:A compound of formula I wherein X is S (the compound of formula IV) can be prepared e.g. by reacting the compound of formula R<1>-SH with the hydrochloride of the compound of formula III (Y is halogen) in the presence of a base. Another compound of formula I wherein X is group of formula II can be synthesized by oxidizing the compound of formula IV.